Cingulate Inc (CING)

$0.80 0.01 (1.51%)

15:59 EDT CING Stock Quote Delayed 30 Minutes

CING Stock Earnings: Cingulate Beats EPS for Q1 2024

By InvestorPlace Earnings May 8, 2024

CING stock results show that Cingulate beat analyst estimates for earnings per share the first quarter of 2024.

Why Is Cingulate (CING) Stock Up 160% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Why Is Cingulate (CING) Stock Up 72% Today?

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 16,874

Day's Range $0.77 - $0.80

52-Week Range $0.28 - $12.70

Dividend & Yield N/A (N/A)

CING Stock Predictions, Articles, and Cingulate Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Feb 24, 2023

It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Dec 9, 2021

Good morning, trader! It's time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday!

Cingulate stock sinks after it prices its public offering to raise $7.5M (NASDAQ:CING)

From Seeking Alpha Feb 2, 2024

Cingulate announces $7.5M public offering, offering 3.75M shares and warrants at $2 per share with an exercise price of $2 per share.

Cingulate promotes Jennifer Callahan to CFO (NASDAQ:CING)

From Seeking Alpha Jan 29, 2024

Cingulate promotes Jennifer Callahan to Chief Financial Officer, succeeding retired CFO Lou Van Horn.

Cingulate files to sell common stock and warrants (NASDAQ:CING)

From Seeking Alpha Jan 15, 2024

Cingulate files prospectus for proposed common stock offering without disclosing amount. This is not an offer to sell securities.

Cytokinetics, Burford Capital, Cipher Mining among premarket gainers' pack

From Seeking Alpha Dec 27, 2023

First Wave BioPharma FWBI +107% on plans to sell niclosamide program. Cingulate (CING) +89%. Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy. Jet.AI (JTAI) +38%.

Laidlaw cuts Cingulate to hold, cites dwindling resources (NASDAQ:CING)

From Seeking Alpha Dec 22, 2023

Laidlaw downgraded Cingulate (CING) to hold and dropped its price target over concerns about the company's financial stability. Read more here.

Maxim Group Remains a Buy on Cingulate Inc (CING)

From TipRanks Dec 8, 2022

Maxim Group analyst Naz Rahman maintained a Buy rating on Cingulate Inc (CING – Research Report) yesterday and set a price target of $3.00. The com...

ADVERTISEMENT